<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Anti-CD20 monoclonal antibodies (MAbs) offer new options for patients with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, needed because existing therapies have many limitations </plain></SENT>
<SENT sid="1" pm="."><plain>The unconjugated, chimeric anti-CD20 antibody, Rituximab (MabThera(R), Rituxan(R)), has recently been approved in the USA for patients with relapsed or refractory, low-grade or follicular, B-cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and in Europe for therapy of relapsed stage III/IV follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In the pivotal study of Rituximab, an overall response rate of 50% was achieved with median time to progression in responders of 13.2 months </plain></SENT>
<SENT sid="3" pm="."><plain>Studies are ongoing with the 90Y-labelled murine anti-CD20 antibody, IDEC-Y2B8 </plain></SENT>
<SENT sid="4" pm="."><plain>The response rate in a Phase I/II study in low-grade and intermediate-grade patients was 67% </plain></SENT>
</text></document>